HIV/hepatitis B virus co-infection: current challenges and new strategies.
J Antimicrob Chemother
; 65(1): 10-7, 2010 Jan.
Article
en En
| MEDLINE
| ID: mdl-19900950
ABSTRACT
Chronic hepatitis B virus (HBV) infection, which affects 7%-10% of HIV-infected patients, is associated with an increased frequency of AIDS-related and non-AIDS-related clinical endpoints, such as end-stage liver diseases including cirrhosis and hepatocellular carcinoma. Broad access to a very efficient antiviral therapy containing nucleos(t)ide analogues with dual activity against HBV and HIV reverse transcriptases has initiated a transition in the paradigm of HBV control in the context of HIV-induced immunosuppression. The control of viral replication is not currently such a problem, but preventing the emergence of HBV polymerase and surface gene mutants after prolonged exposure to nucleos(t)ides and their consequences in terms of HBV vaccine escape are the next long-term challenges. Another challenge is the prevention of end-stage liver disease in an ageing population, in whom non-invasive markers of liver fibrosis, although used more frequently as a substitute for liver biopsy, are not the panacea. Finally, access to prevention, diagnosis, care and treatment of HBV infection remains a major issue in developing countries, including most regions of Africa and Asia, where HBV is endemic and the epidemic of HIV infection is still thriving.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Hepatitis B Crónica
Tipo de estudio:
Etiology_studies
Límite:
Animals
/
Humans
País/Región como asunto:
Africa
/
Asia
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
2010
Tipo del documento:
Article
País de afiliación:
Francia